Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

• Entrectinib: Inhibitor of the tyrosine kinases TrkA, TrkB, TrkC, ROS1, and ALK
• Alectinib: ALK kinase inhibitor

In this study, the sponsor and investigators want to learn:

• How much of the study drug / agent can be given with an acceptable level of side effects
• The effects of the study drug (good and bad)
• How much of the study drug / agent is absorbed into the blood and how fast it is removed
• How the study drug / agent is acting on your body
• If research tests can be used in the future to predict who will benefit from the study drug

In this study, you will receive the study drug Entrectinib, given as a capsule. You will take three capsules once a day (depending on your weight and height, your study doctor may give study drug in a different way). While you are receiving study treatment in this study, you will have clinic visits about every 2 weeks for the first 3 months and then once a month thereafter. After completing 1 year of study treatment, clinic visits may occur less often (once every three months).

In this study, you will receive the study drug alectinib, given as a capsule. You will take four capsules twice a day